26Jul2022

ERC Granted FDA Fast Track Designation for Sitoiganap in Patients with Recurrent Glioblastoma
30Jun2022

ERC Announces Publication of Positive Efficacy Data with Sitoiganap in Patients with Recurrent Glioblastoma

ERC Belgium S.A. (ERC), announced publication of its most recent efficacy data in the May 2022 edition of Frontiers in Oncology.
10Jun2022

ERC Belgium balance sheet for the financial year ending 31 Dec 2021

Download the ERC Belgium balace sheet for the financial year ending 31 Dec 2021.
24Dec2021

CEO STATEMENT 2021/2022

07Apr2021

ERC-USA Announces FDA Recommendation for Early Termination of Phase 2 Clinical Trial of ERC1671 (Gliovac or Sitoiganap) and Application for Registration Trial for Treatment of Glioblastoma
01May2020

ERC receives a positive Opinion to commence a paediatric investigation plan(clinical trial) from the European Medicines Agency.
30Apr2020

12 Month Progress Report 30/04/2019-30/04/2020
20Apr2020

LATEST SITUATION – CEO STATEMENT
01Apr2020

In Q2 2020 after enrolling about 40 patients in the Phase II clinical trial, ERC will submit its request for commercialization in the USA
27Dec2019

Abigail-Alliance Humanitarian of the year award 2019

 In recognition of ERC’s commitment, Doctor Stathopoulos has received the Abigail-Alliance award for Humanitarian of the year 2019 for the ERC RTT program and Gliovac/ERC1671. Click...
27Feb2019

Decision of National organisation of Medicines of Greece

Issue: CU-10/JAN/2019
Approval of Temporary Individual Access to Early Access to the Medicinal Product GLIOVAC in Greece.
31Aug2018

12 month progress report 31/08/2017-31/09/2018

ERC has made significant progress over the past 12 months in moving our experimental vaccine Gliovac (also know as ERC1671) toward commercialization.
08Jul2016

New production site in the Netherlands

ERC has opened a new additional production site in the Netherlands dedicated to GMP-based production of Gliovac/ERC1671 against glioblastoma brain cancer, as well as vaccines based on the same,...
15May2016

Approval for open phase II study

ULB Belgium’s ethical commitee has approved the protocol for an open phase II study of standard treatments in combination with Gliovac/ERC1671 vs standard treatments ...
29Mar2016

Interest to use our technology for other cancers

Based on the visibility of preliminary results for GBM, independent groups expressed their strong interest to use the technology for other cancers.